JPWO2021076941A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021076941A5
JPWO2021076941A5 JP2022522814A JP2022522814A JPWO2021076941A5 JP WO2021076941 A5 JPWO2021076941 A5 JP WO2021076941A5 JP 2022522814 A JP2022522814 A JP 2022522814A JP 2022522814 A JP2022522814 A JP 2022522814A JP WO2021076941 A5 JPWO2021076941 A5 JP WO2021076941A5
Authority
JP
Japan
Prior art keywords
capsid protein
sequence
raav vector
nucleic acid
vector according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022522814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500793A (ja
JP2023500793A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056051 external-priority patent/WO2021076941A1/en
Publication of JP2023500793A publication Critical patent/JP2023500793A/ja
Publication of JP2023500793A5 publication Critical patent/JP2023500793A5/ja
Publication of JPWO2021076941A5 publication Critical patent/JPWO2021076941A5/ja
Priority to JP2025233417A priority Critical patent/JP2026041903A/ja
Pending legal-status Critical Current

Links

JP2022522814A 2019-10-16 2020-10-16 アルツハイマー病に対する遺伝子治療方法 Pending JP2023500793A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025233417A JP2026041903A (ja) 2019-10-16 2025-12-05 アルツハイマー病に対する遺伝子治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962915988P 2019-10-16 2019-10-16
US62/915,988 2019-10-16
PCT/US2020/056051 WO2021076941A1 (en) 2019-10-16 2020-10-16 Gene therapy for alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025233417A Division JP2026041903A (ja) 2019-10-16 2025-12-05 アルツハイマー病に対する遺伝子治療方法

Publications (3)

Publication Number Publication Date
JP2023500793A JP2023500793A (ja) 2023-01-11
JP2023500793A5 JP2023500793A5 (https=) 2023-10-24
JPWO2021076941A5 true JPWO2021076941A5 (https=) 2023-10-24

Family

ID=73288693

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022522814A Pending JP2023500793A (ja) 2019-10-16 2020-10-16 アルツハイマー病に対する遺伝子治療方法
JP2025233417A Pending JP2026041903A (ja) 2019-10-16 2025-12-05 アルツハイマー病に対する遺伝子治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025233417A Pending JP2026041903A (ja) 2019-10-16 2025-12-05 アルツハイマー病に対する遺伝子治療方法

Country Status (13)

Country Link
US (1) US20230405148A1 (https=)
EP (1) EP4045653A1 (https=)
JP (2) JP2023500793A (https=)
KR (1) KR20220082050A (https=)
CN (1) CN114761569A (https=)
AU (2) AU2020367437B2 (https=)
BR (1) BR112022007010A2 (https=)
CA (1) CA3157864A1 (https=)
CO (1) CO2022006367A2 (https=)
IL (1) IL292148A (https=)
MX (1) MX2022004524A (https=)
WO (1) WO2021076941A1 (https=)
ZA (1) ZA202205344B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7616995B2 (ja) * 2018-11-28 2025-01-17 プリベイル セラピューティクス,インコーポレーテッド 神経変性疾患のための遺伝子治療
EP4508213A1 (en) * 2022-04-12 2025-02-19 uniQure biopharma B.V. Nucleic acid regulation of apoe
EP4551711A1 (en) * 2022-07-08 2025-05-14 Cornell University Methods and pharmaceutical compositions for the treatment and the prevention of alzheimers disease
WO2025213111A2 (en) * 2024-04-05 2025-10-09 Cornell University Aav expression of mirna to suppress human apoe mrna

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
ATE163230T1 (de) 1993-03-09 1998-02-15 Epic Therapeutics Inc Makromolekulare mikropartikel und verfahren zu ihrer herstellung
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5603960A (en) 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6342390B1 (en) 1994-11-23 2002-01-29 The United States Of America As Represented By The Secretary Of Health And Human Services Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
CA2267930A1 (en) 1996-10-09 1998-04-16 Nobuyuki Takechi A method for producing a microparticle
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
WO2007041190A2 (en) 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
CA2643048A1 (en) * 2006-02-21 2007-08-30 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
KR20140102327A (ko) * 2007-02-06 2014-08-21 유태준 유전자 요법을 사용한 신경퇴행성 질환의 치료 및 예방
US9572894B2 (en) 2010-10-18 2017-02-21 The University Of Iowa Research Foundation Biodegradable particulate formulations
WO2012115806A1 (en) 2011-02-24 2012-08-30 University Of Iowa Research Foundation New biodegradable polymers with sulfenamide bonds for drug delivery applications
JP6469000B2 (ja) * 2012-05-18 2019-02-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション アミロイドの沈着を処置するための方法および組成物
WO2013181618A2 (en) * 2012-05-31 2013-12-05 The Trustees Of Columbia University In The City Of New York Methods to treat alzheimer's disease using apoe inhibitors
MX2016006584A (es) * 2013-11-20 2016-09-06 Univ Iowa Res Found Métodos y composiciones para tratar los depósitos de amiloide.
WO2018045347A1 (en) * 2016-09-02 2018-03-08 Spark Therapeutics, Inc. Methods and vectors for treating cns disorders
US11071791B2 (en) * 2018-01-26 2021-07-27 Wisconsin Alumni Research Foundation Vector for gene silencing and replacement and methods of use thereof
JP7616995B2 (ja) * 2018-11-28 2025-01-17 プリベイル セラピューティクス,インコーポレーテッド 神経変性疾患のための遺伝子治療

Similar Documents

Publication Publication Date Title
JP7413256B2 (ja) 神経変性疾患の遺伝子治療
US20250161485A1 (en) Aav capsid variants and uses thereof
JP7616995B2 (ja) 神経変性疾患のための遺伝子治療
JP2020533959A5 (https=)
JP2023510799A (ja) 併用療法のためのウイルスベクター
RU2018145010A (ru) Оптимизированные гены и экспрессионные кассеты cln1, и их применение
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
WO2025038430A1 (en) Aav capsid variants and uses thereof
JP2021534766A5 (https=)
US20200283800A1 (en) Gene therapies for neurodegenerative diseases
JPWO2021076941A5 (https=)
JPWO2019222354A5 (https=)
JPWO2021163556A5 (https=)
JPWO2021108809A5 (https=)
JPWO2021081236A5 (https=)
JP2023551254A (ja) 神経変性疾患のための遺伝子治療
JP2020533313A5 (https=)
JPWO2023198745A5 (https=)
JPWO2023278449A5 (https=)
EP4281561A1 (en) Modulation of aav-based gene expression
RU2020141012A (ru) Композиции и способы снижения сплайсопатии и лечения расстройств, ассоциированных с доминированием рнк
JPWO2023086966A5 (https=)
JPWO2023060215A5 (https=)
JPWO2022115535A5 (https=)
JPWO2020160121A5 (https=)